Keith Robison has a post on his Omics! Omics! blog about Roche's seemingly unquenchable thirst for acquisition targets. Robison recaps the recent acquisitions of 454 and NimbleGen, as well as the company's currently-in-play bid for Ventana, and ponders how these units could function together as well as what kind of technology might be next on Roche's shopping list.